An informational resource for healthcare professionals interested in stroke reduction, venous protection, and vascular protection. Stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events through the many resources found in the tabs listed here.
Educational resources about reducing stroke by understanding the underlying thrombotic risk in patients with or without atrial fibrillation.
Educational resources about the underlying thrombotic risk of major adverse cardiac events in patients with vascular diseases such as Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Heart Failure.
While we in the medical community can appropriately pat ourselves on the back for winning numerous battles, the war on atherosclerosis is not over. We have not cured atherosclerosis.
Secondary prevention therapies and positive lifestyle interventions benefit high-risk patients with PAD and concomitant CAD.
Recent developments in guideline-recommended therapy and medical care for patients with PAD.
Advocacy and education initiatives are key to improving awareness of PAD among patients and providers.
This discussion examines heart disease treatment guidelines as they apply to the growing elderly U.S. population.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.